Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

The company said it was reviewing Mounjaro pricing with other governments and expected to make similar adjustments in certain ...

Ozempic sales have risen five-fold after a 126 per cent rise in the price of the Mounjaro drug due to pressure from US ...

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

Novo Nordisk's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Google issues cybersecurity warning as hackers exploit AI to steal passwords. FDA warns against unapproved sunscreens. Lilly ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...